Please login to the form below

Not currently logged in

European approval for Abbott's Humira in children with Crohn's disease

Adds to existing autoimmune indications for company’s top-selling drug

Children with Crohn's disease in Europe will now have access to Abbott's Humira following its approval by the European Commission (EC) in a paediatric indication.

The indication is for use of the inject table TNF blocker in patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy.

It is the latest in a long list of approvals in autoimmune indications for the company's lead product, and should help boost the drug's slowing sales, which contributed to flat growth for Abbott during the third quarter of 2012.

According to Abbott, paediatric Crohn's disease, which is a type of inflammatory bowel disease, affects up to 200,000 children worldwide.

Aside from abdominal pain, weight loss and diarrhoea, which are also found in adults, symptoms specific to children include delayed growth and/or puberty.

"The availability of Humira for this patient population addresses an unmet need throughout the European Union and reinforces Abbott's long-standing commitment to patients with inflammatory bowel disease," said Dr John Medich, divisional vice president, clinical development, immunology, Abbott.

"With this approval, these young patients and their care providers may now have access to a therapy that can help manage their disease and be administered at home."

Humira (adalimumab) is already available in Europe for adults with moderately to severely active Crohn's disease, as well as a number of inflammatory indications, including rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.

It is by far Abbott's biggest selling product, recording revenues of $6.56bn during the first nine months of 2012, compared to the next biggest selling drug Trilipx/TriCor (fenofibrate) to treat high levels of cholesterol, which made $1.12bn in the same period.

27th November 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...